NasdaqGS - Delayed Quote USD
REGENXBIO Inc. (RGNX)
At close: October 18 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Cash Flow
-191,119.00
-218,407.00
-207,488.00
218,875.00
-54,061.00
--
Investing Cash Flow
85,546.00
190,943.00
-11,929.00
-406,642.00
122,759.00
--
Financing Cash Flow
94,513.00
-34,966.00
-28,840.00
195,250.00
200,214.00
--
End Cash Position
59,795.00
36,552.00
98,982.00
347,239.00
339,756.00
--
Income Tax Paid Supplemental Data
904.00
--
11,812.00
5,996.00
--
904.00
Interest Paid Supplemental Data
--
7,276.00
23,117.00
21,635.00
--
--
Capital Expenditure
-3,596.00
-9,960.00
-30,724.00
-84,175.00
-26,869.00
--
Issuance of Capital Stock
138,129.00
6,700.00
1,742.00
218,206.00
1,799.00
--
Free Cash Flow
-194,715.00
-228,367.00
-238,212.00
134,700.00
-80,930.00
--
12/31/2019 - 9/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRTA Prothena Corporation plc
17.11
+0.29%
QURE uniQure N.V.
6.42
+2.23%
APLS Apellis Pharmaceuticals, Inc.
28.00
+0.29%
VYGR Voyager Therapeutics, Inc.
8.07
+0.75%
CLSD Clearside Biomedical, Inc.
1.1500
0.00%
VRDN Viridian Therapeutics, Inc.
24.98
+2.97%
MGTX MeiraGTx Holdings plc
6.14
+3.37%
RCKT Rocket Pharmaceuticals, Inc.
18.82
+2.12%
ADVM Adverum Biotechnologies, Inc.
8.48
+4.95%
URGN UroGen Pharma Ltd.
12.73
-0.86%